Table: Daito -6-MTH group results
Jan 13 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Nov 30, 2016 Nov 30, 2015 May 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 19.22 18.32 38.10
(+4.9 pct) (+9.8 pct) (+4.8 pct)
Operating 2.13 1.85 3.70
(+14.9 pct) (+4.0 pct) (+4.1 pct)
Recurring 2.08 1.89 3.75
(+10.4 pct) (+9.6 pct) (+1.0 pct)
Net 1.42 1.27 2.60
(+12.3 pct) (+14.2 pct) (+1.3 pct)
EPS 113.79 yen 101.31 yen 207.76 yen
Ann Div 30.00 yen 30.00 yen
-Q2 div 15.00 yen 15.00 yen
-Q4 div 15.00 yen 15.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results